我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

多支冠状动脉病变患者1911例PCI二年疗效(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第3期
页码:
302-305
栏目:
临床研究
出版日期:
2007-06-01

文章信息/Info

Title:
Twoyear therapeutic effect of PCI in 1911 patients with multivessel coronary artery disease
作者:
韩雅玲; 李成洋; 王效增; 荆全民; 王守力; 马颖艳
沈阳军区总医院心内科，辽宁 沈阳 110016
Author(s):
HAN Yaling;  LI Chengyang;  WANG Xiaozeng;  JING Quanmin;  WANG Shouli;  MA Yingyan
Department of Cardiology, General Hospital of Shenyang Military Area Command, Shenyang 110016, Liaoning, China
关键词:
多支冠状动脉病变; 血运重建; 主要不良心脏事件
Keywords:
multivessel coronary artery disease; revascularization; major adverse cardiac events
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 评价多支冠状动脉病变(MVD)通过经皮冠状动脉介入(PCI)进行血运重建的长期疗效。方法 1995年6月~2003年12月连续2 028例在我院成功接受PCI的MVD患者，对其心绞痛复发率、造影复查再狭窄率和主要不良心脏事件(MACE)的发生率进行回顾分析。结果 2 028例MVD患者，完全性血运重建率86.2%(1 748／2 028)，住院期间共死亡26例（总病死率1.3%），对存活出院的2 002例患者中的1 911例随访24个月，随访率95.5%，其心绞痛复发率、造影复查再狭窄率和MACE发生率分别为10.7%、14.6%、25.4%，其中1 754例植入普通金属支架（BMS），157例植入药物洗脱支架（DES）。尽管DES组患者冠心病危险因素多、病变程度复杂，不稳定心绞痛占61.8%、糖尿病占41.4%、慢性完全闭塞病变（CTO）占37.6%、3支病变占58.0%，但心绞痛复发率、造影复查再狭窄率和MACE发生率均显著低于BMS组（分别为4.5% vs 11.2%, 3.2% vs 15.7%, 8.9% vs 26.9%, 均P<0.01）。结论 PCI进行血运重建是治疗MVD的有效方法，但仍存在BMS支架术后不良事件发生率高，DES用于治疗MVD具有更好的长期疗效。
Abstract:
AIM To retrospectively investigate the longterm therapeutic effect of percutaneous coronary intervention (PCI) on revascularization in patients with multivessel coronary artery disease (MVD). METHODS From June 1995 to December 2003, a total of 2028 patients with MVD were treated by PCI and the rates of angina recurrence, angiographic restenosis and major adverse cardiac events (MACE) were retrospectively analyzed. RESULTS Among the 2028 patients, complete revascularization rate was 86.2% (1748／2028). The total inhospital mortality rate was 1.3% (26/2028) and 2002 were discharged after treatment, of whom 1911 patients (95.5%) were followed up for 24 months. The rates of angina recurrence, angiographic restenosis and MACE were 10.7%, 14.6% and 25.4%, respectively. Of the 1911 cases, 1754 patients had been treated by bare metal stent（BMS）and 157 patients treated by drugeluting stent (DES). Although the patients treated by DES had more risk factors and more complex coronary lesions ［61.8% with unstable angina, 41.4% with diabetes, 37.6% with chronic total occlusion (CTO) and 58.0% with triplevessel disease］ , the postPCI rates of angina recurrence, angiographic restenosis and MACE were significantly lower than those in patients treated by BMS （4.5% vs 11.2%, 3.2% vs 15.7%, 8.9% vs 26.9%, P<0.01）. CONCLUSION The PCI revascularization is an effective treatment in patients with MVD, but the patients treated with BMS may have relatively higher MACE rate. DES has better longterm therapeutic effect in patients with MVD.

参考文献/References

［1］ Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guidelines update for the management of patients with unstable angina and nonSTsegment elevation myocardial infarctionsummary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)［J］. J Am Coll Cardiol,2002,40(7):13661374.

［2］ 韩雅玲,王耿,荆全民,等. 急性冠状动脉综合征介入治疗4670例近期疗效的评价［J］. 中华医学杂志，2005,85(15):1040-1044.

［3］ Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty )［J］. J Am Coll Cardiol ,2001,37(8):2215-2239.

［4］ Serruys PW, Unger F, Sousa JE, et al. Comparison of coronaryartery bypass surgery and stenting for the treatment of multivessel disease［J］. N Engl J Med, 2001,344（15）:1117-1124.

［5］ Legrand VM, Serruys PW, Unger F, et al.Threeyear outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease［J］. Circulation, 2004，109 (9): 1114-1120.

［6］ Lowe HC, Oesterle SN, Khachigian LM, et al. Coronary instent restenosis: current status and future strategies［J］. J Am Coll Cardiol, 2002, 39(2):183-193.

［7］ Serruys PW, for ARTSⅡInvestigators. ARTSⅡ:Arterial Revascularization Therapies Study Part Ⅱof the sirolimuseluting stent in the treatment of patients with multivessel de novo coronary artery lesions. Late Breaking Clinical Trial. Presented at : the American College of Cardiology 54th Annual Meeting［C］. Orlando, Florida: March 2005.

［8］ Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxelversus sirolimuseluting stent for coronary artery disease in an unselected population: oneyear results of the TaxusStent Evaluated at Rotterdam Cardiology Hospital (TSEARCH) registry［J］. J Am Coll Cardiol, 2005, 45(7):11351141.

备注/Memo

备注/Memo:
收稿日期：2006-05-23.基金项目:军队“十五”重点课题基金资助(No.01Z001) 通讯作者:韩雅玲,主任医师,主要研究方向为冠心病介入诊治Email: hanyal@mail.sy.ln.cn
更新日期/Last Update: